FSD Pharma 向澳大利亚伦理委员会提交了神经保护药物 Lucid-21-302 的第 1 阶段多次递增剂量试验申请。 FSD Pharma submits Phase-1 Multiple Ascending Doses trial application for neuroprotective drug Lucid-21-302 to Australian ethics committee.

FSD Pharma 已向澳大利亚人类伦理审查委员会提交了其神经保护药物 Lucid-21-302 的 I 期多次递增剂量临床试验申请。 FSD Pharma has submitted a Phase-1 Multiple Ascending Doses clinical trial application for its compound Lucid-21-302, a neuroprotective drug, to an Australian human ethics review committee. 该试验旨在评估该化合物对健康成人的安全性和药代动力学。 The trial aims to evaluate the safety and pharmacokinetics of the compound in healthy adults. 该申请是在完成第一阶段单次递增剂量试验之后进行的。 The application follows a completed Phase-1 Single Ascending Dose trial.